Form 4: Maze Therapeutics Insider Sells Shares Under 10b5-1 Plan

Maze Therapeutics' CSBO, Atul Dandekar, sold 7,500 shares of common stock for $10.42 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Atul Dandekar, Chief Strategy and Business Officer (CSBO) of Maze Therapeutics, Inc., reported a transaction on May 29, 2026.
• Dandekar sold 7,500 shares of common stock at a weighted average price of $26.34 per share, with individual sales ranging from $26.03 to $26.64.
• This sale was executed as part of a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Following the sale, Dandekar beneficially owns 24,808 shares of common stock directly.
• Additionally, Dandekar acquired 7,500 stock options at an exercise price of $10.42, which are fully vested and expire on April 11, 2031.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sale can be perceived negatively, the execution under a pre-established 10b5-1 plan mitigates concerns about insider trading. The acquisition of vested options is a standard compensation event.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-trading-related activity.
• The stock options acquired are fully vested, suggesting the reporting person has met the necessary conditions for ownership.
• The exercise price of the stock options ($10.42) is significantly lower than the sale price of the common stock ($26.34), potentially indicating a favorable position for the reporting person.

Negatives

• A significant number of shares (7,500) were sold by a key executive.
• The sale represents a reduction in direct beneficial ownership of common stock by the CSBO.

Risks

• The sale of shares by a key executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the timing of the sale relative to any company news is not detailed, which could raise questions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.64 per share, inclusive.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to diversify their holdings or manage personal finances without creating the appearance of trading on material non-public information. The specific details of the sale price relative to the option exercise price are noteworthy.

Stakeholder Impact

• Shareholders: May view the sale by a key executive with caution, although the 10b5-1 plan provides some reassurance.
• Employees: The sale might not have a direct impact, but could influence internal sentiment depending on broader company performance.
• Management: The transaction is a personal financial management action by the CSBO.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan.
• The acquired stock options can be exercised according to their terms until expiration.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Maze Therapeutics, Stock Options, Share Sale, Beneficial Ownership, Executive Compensation, SEC Filing